- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01273233
Safety of an Inactivated Enterovirus Type 71 Vaccine in Healthy Adults
March 13, 2013 updated by: Sinovac Biotech Co., Ltd
A Blinded, Randomized and Controlled Clinical Trial of An Inactivated Enterovirus Type 71 Vaccine in Healthy Adults
A blind, randomized and placebo-controlled clinical trial with Inactivated Enterovirus Type 71 Vaccines in healthy adults
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
A total of 36 eligible subjects aged from 18 to 49 years will be enrolled in the study, they will be randomized to receive two different dosage of vaccine candidate or placebo to evaluate the safety of this vaccine in adults
Study Type
Interventional
Enrollment (Actual)
36
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Guangxi
-
Nanning, Guangxi, China
- GuangXi Center for Diseases Control and Prevention
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 49 years (Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Healthy males and females, aged from 18 to 49 years old. Health is determined by medical history, physical examination, laboratory examination and clinical judgment of the investigator
- Provided legal identification for the sake of recruitment.
- Subjects are able to understand and sign informed consents.
Exclusion Criteria:
- Histroy of Hand-foot-mouth Disease
- Women of lactation, pregnancy or about to be pregnant in 60 days
- Subject that has allergic history of vaccine, or allergic to any ingredient of vaccine
- Serious adverse reactions to vaccines such as anaphylaxis, hives, respiratory difficulty, angioedema, or abdominal pain
- Congenital malformations or developmental disorders, genetic defects, or severe malnutrition
- Epilepsy, seizures or convulsions history, or family history of mental illness
- Autoimmune disease or immunodeficiency, or parents, brothers and sisters have autoimmune diseases or immunodeficiency
- History of asthma, angioedema, diabetes or malignancy
- History of thyroidectomy or thyroid disease that required medication within the past 12 months
- Bleeding disorder diagnosed by a doctor (e.g. factor deficiency, coagulopathy, or platelet disorder requiring special precautions) or significant bruising or bleeding difficulties with IM injections or blood draws
- Asplenia, functional asplenia or any condition resulting in the absence or removal the spleen
- Acute illness or acute exacerbation of chronic disease within the past 7 days
- Any history of immunosuppressive medications or cytotoxic medications or inhaled corticosteroids within the past six months (with the exception of corticosteroid nasal spray for allergic rhinitis or topical corticosteroids for an acute uncomplicated dermatitis)
- History of any blood products within 3 months
- Administration of any live attenuated vaccine within 28 days
- Administration of subunit or inactivated vaccines ,e.g., pneumococcal vaccine, or allergy treatment within 14 days
- Axillary temperature > 37.0 centigrade before vaccination
- Abnormal laboratory parameters before vaccination
- Any medical, psychiatric, social condition, occupational reason or other responsibility that, in the judgment of the investigator, is a contraindication to protocol participation or impairs a volunteer's ability to give informed consent
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Group 1: 200U EV71 vaccine
12 adults received 3 doses of 200U EV71 vaccine 14 days apart
|
A Sinovac EV71 vaccine contains inactivated EV71 virus, aluminum hydroxide, sodium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate and injection water.
The EV71 vaccine is supplied in one mono-dose vial containing 0.5 mL of viral suspension with EV71 virus antigen of 200U and 400U (Elisa unit)
Other Names:
|
Experimental: Group 2: 400U EV71 vaccine
12 adults received 3 doses of 400U EV71 vaccine 14 days apart
|
A Sinovac EV71 vaccine contains inactivated EV71 virus, aluminum hydroxide, sodium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate and injection water.
The EV71 vaccine is supplied in one mono-dose vial containing 0.5 mL of viral suspension with EV71 virus antigen of 200U and 400U (Elisa unit)
Other Names:
|
Placebo Comparator: Group 1: Placebo
6 adults received 3 doses of placebo 14 days apart
|
Placebo is suspension with a little ivory precipitation, composition of which is aluminum hydroxide diluents.
Other Names:
|
Placebo Comparator: Group 2: Placebo
6 adults received 3 doses of placebo 14 days apart
|
Placebo is suspension with a little ivory precipitation, composition of which is aluminum hydroxide diluents.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To evaluate the safety and tolerability of the inactivated Enterovirus Type 71 Vaccine in adults by different doses
Time Frame: 3 months
|
3 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Yan-ping Li, MD, Guangxi Centers for Disease Control and Prevention
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
December 1, 2010
Primary Completion (Actual)
February 1, 2011
Study Completion (Actual)
February 1, 2011
Study Registration Dates
First Submitted
January 7, 2011
First Submitted That Met QC Criteria
January 7, 2011
First Posted (Estimate)
January 10, 2011
Study Record Updates
Last Update Posted (Estimate)
March 15, 2013
Last Update Submitted That Met QC Criteria
March 13, 2013
Last Verified
March 1, 2013
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- EV71-1001-Ia
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Infection; Viral, Enterovirus
-
Sinovac Biotech Co., LtdWithdrawnInfection, Viral, EnterovirusChina
-
Sinovac Biotech Co., LtdCompletedInfection, Viral, EnterovirusChina
-
Sinovac Biotech Co., LtdCompletedHand-foot-mouth Disease | Infection; Viral, EnterovirusChina
-
Provention Bio, Inc.CompletedViral; Infection, Coxsackie(Virus)Finland
-
Medigen Vaccine Biologics Corp.CompletedEnterovirus 71 InfectionTaiwan, Vietnam
-
Shaare Zedek Medical CenterWithdrawnViral MeningitisIsrael
-
Bayi Children's Hospital Affiliated to PLA Army...UnknownEnterovirus Infection During Perinatal PeriodChina
-
Norwegian Institute of Public HealthInternational Centre for Diarrhoeal Disease Research, Bangladesh; Sykehuset...CompletedHepatitis E InfectionBangladesh
-
AIDS Clinical Trials GroupNational Institute of Allergy and Infectious Diseases (NIAID)CompletedHepatitis | HIV-1 InfectionUnited States
-
Trek Therapeutics, PBCCompletedChronic Hepatitis C | Hepatitis C Genotype 1 | Hepatitis C (HCV) | Hepatitis C Viral InfectionUnited States, New Zealand
Clinical Trials on Inactivated Enterovirus Type 71 Vaccine
-
Sinovac Biotech Co., LtdCompletedHand-foot-mouth Disease | Infection; Viral, EnterovirusChina
-
Sinovac Biotech Co., LtdNot yet recruitingHand, Foot and Mouth DiseaseChina
-
International Centre for Diarrhoeal Disease Research...CompletedHand Foot & Mouth DiseaseBangladesh
-
Beijing Zhifei Lvzhu Biopharmaceutical Co., LtdCompleted
-
Sinovac Biotech Co., LtdRecruitingHand, Foot and Mouth Disease | HerpanginaChina
-
Jiangsu Province Centers for Disease Control and...Institute of Medical Biology, Chinese Academy of Medical SciencesActive, not recruitingHand, Foot and Mouth DiseaseChina
-
Beijing Chaoyang District Centre for Disease Control...UnknownEnterovirus 71 Vaccine
-
Sheba Medical CenterRace Oncology LtdCompletedAcute Myelogenous Leukemia | Allogeneic Stem Cell TransplantationIsrael
-
Sinovac Biotech Co., LtdCompletedHand, Foot and Mouth DiseaseChina
-
Hualan Biological Engineering, Inc.Completed